336 completed, 77 recruiting, 62 unknown, 35 active not recruiting. 105 Phase 3, 98 Not applicable, 64 Phase 2, 48 Phase 4, 30 Phase 1.
Follow Arthritis, Psoriatic: new trials by email Literature Review of Arthritis, Psoriatic trials Research Report on Arthritis, Psoriatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-13 |
| Patient-Reported Outcomes Dashboard With Goal Setting to Support Shared Decision-Making in Inflammatory Arthritis Patient-Reported Outcomes Dashboard With Goal Setting - Arthritis, Psoriatic (PsA), Arthritis, Rheumatoid (RA) | Not applicable | Not yet recruiting | Northwestern University | 160 | 2027-01-01 | 2026-10-15 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| Apremilast and Adalimumab in Psoriatic Arthritis Patients Adalimumab, Apremilast - Psoriatic Arthritis, Ultrasound Assessment | Not applicable | Not yet recruiting | Tanta University | 60 | 2026-12-30 | 2026-09-08 |
| Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA) | Phase 2 | Not yet recruiting | Forward Therapeutics | 210 | 2026-12-01 | 2026-10-09 |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 220 | 2026-10-14 | 2026-10-13 |
| Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients Meibomian Gland Dysfunction, Dry Eye Syndromes | Not yet recruiting | Assiut University | 150 | 2026-10-01 | 2026-09-09 | |
| Disease Impact and Its Correlation With Disease Activity in Psoriatic Arthritis Psoriatic Arthritis | Not yet recruiting | Assiut University | 80 | 2026-10-01 | 2026-08-31 | |
| A Clinical Trial of Antiplatelets in Psoriasis Aspirin, Clopidogrel, Placebo - Psoriasis (PsO), Psoriatic Arthritis (PsA) | Phase 4 | Not yet recruiting | NYU Langone Health | 60 | 2026-09-01 | 2026-08-05 |
| Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study iPROLEPSIS Digital Health Ecossystem - Psoriatic Arthritis (PsA) | Not applicable | Not yet recruiting | Sociedade Portuguesa de Reumatologia | 72 | 2026-09-01 | 2026-09-16 |
| Retinal Capillary Vessel Density and Foveal Avascular Zone Size in Patients With Psoriatic Arthritis: A Case-Control Study. OCTA-SCP, OCTA-DCP, OCTA-RPC - Arthritic Psoriasis, Psoriasis (PsO) | Recruiting | Bursa Yuksek Ihtisas Training and Research Hospital | 135 | 2026-09-01 | 2026-10-13 | |
| A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants DRL_AB - Healthy Volunteers | Phase 1 | Not yet recruiting | Dr. Reddy's Laboratories Limited | 160 | 2026-08-19 | 2026-08-04 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-10-05 |
| Ultrasound and Shear Wave Elastography Assessment of Entheses in Psoriatic Arthritis Grayscale Ultrasonography, Power Doppler Ultrasonography, and Shear Wave Elastography - Psoriatic Arthritis, Enthesitis | Not yet recruiting | Marmara University | 60 | 2026-07-27 | 2026-08-25 | |
| A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis TQH3906 Capsule, TQH3906 Placebo Capsule, Tofacitinib Citrate Tablet 5 mg - Psoriatic Arthritis | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 156 | 2026-07-16 | 2026-09-02 |
| Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) CBP-0276 capsules 100mg, Placebo - Arthritic Psoriasis | Phase 2 | Not yet recruiting | Clarent Biopharma, Inc. | 240 | 2026-07-01 | 2026-07-16 |
| Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease Deucravacitinib, Placebo - Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | University of Texas Southwestern Medical Center | 128 | 2026-06-16 | 2026-09-01 |
| Transcutaneous Auricular Vagus Nerve Stimulation in Psoriatic Arthritis Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) - Psoriatic Arthritis | Not applicable | Recruiting | Marmara University | 15 | 2026-06-02 | 2026-06-17 |
| Inflammation Digital Biomarkers Validation Study Psoriatic Arthritis, Psoriasis (PsO) | Not yet recruiting | University of Oxford | 3458 | 2026-06-01 | 2026-05-22 | |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
Showing 20 of 592. Sign in to see all of them.
Arthritis, Rheumatoid (180) · Psoriasis (127) · Spondylitis, Ankylosing (100) · Arthritis (56) · Crohn Disease (46) · Spondylarthritis (39) · Colitis, Ulcerative (34) · Axial Spondyloarthritis (31) · Lupus Erythematosus, Systemic (25) · Autoimmune Diseases (20) · Inflammatory Bowel Diseases (18) · Spondylarthropathies (18) · Arthritis, Juvenile (17) · Sjogren's Syndrome (14)
Bone Diseases (592) · Skin and Connective Tissue Diseases (592) · Spinal Diseases (592) · Skin Diseases, Papulosquamous (590) · Musculoskeletal Diseases (589) · Spondylitis (586) · Joint Diseases (583) · Skin Diseases (582) · Spondylarthropathies (574) · Spondylarthritis (553) · Arthritis (536) · Psoriasis (465) · Immune System Diseases (197) · Connective Tissue Diseases (190) · Rheumatic Diseases (180)
Adalimumab (39) · secukinumab (34) · Etanercept (29) · Methotrexate (26) · apremilast (23) · Infliximab (18) · golimumab (18) · guselkumab (18) · Ustekinumab (16) · bimekizumab (15) · tofacitinib (13) · ixekizumab (12) · risankizumab (11) · Surveys and Questionnaires (10) · upadacitinib (10)
Novartis Pharmaceuticals (27) · AbbVie (25) · Amgen (20) · Pfizer (20) · Janssen Research & Development, LLC (19) · UCB Biopharma SRL (12) · Bristol-Myers Squibb (11) · AbbVie (prior sponsor, Abbott) (9) · University of Oxford (9) · Chinese University of Hong Kong (8) · Diakonhjemmet Hospital (8) · University of Pennsylvania (8) · Wyeth is now a wholly owned subsidiary of Pfizer (8) · Eli Lilly and Company (7) · Abbott (6)
United States (188) · Germany (106) · Canada (98) · Spain (93) · United Kingdom (93) · France (91) · Poland (89) · Czechia (72) · Hungary (64) · Italy (62) · Russia (60) · Australia (59) · Belgium (51) · Bulgaria (46) · Denmark (36)
Alexis Ogdie-Beatty, MD, MSCE (3) · Eisa Mohammed Hegazy, Professor (3)
PMID 37316690, PMID 38446397, PMID 38488975, PMID 39120849, PMID 40194794, PMID 41807031, PMID 34795065, PMID 35393269, PMID 36178584, PMID 36642439, PMID 37906417, PMID 39120848, PMID 40241921, PMID 30018799, PMID 30739254, PMID 31077258, PMID 31112005, PMID 31203228, PMID 31909868, PMID 31964419, PMID 32006348, PMID 32816215, PMID 34536218, PMID 34870800, PMID 36526796, PMID 36931693, PMID 36958766, PMID 38754125, PMID 39215949, PMID 39534481, PMID 40014255, PMID 40347389, PMID 41148555, PMID 41381988, PMID 41396391, PMID 41838419, PMID 42152504, PMID 42386286, PMID 42860055, PMID 21994233, PMID 25593233, PMID 27098404, PMID 27483458, PMID 29045207, PMID 29045212, PMID 30373651, PMID 30414064, PMID 30680661, PMID 30696483, PMID 30886974
2016 (13), 2023 (13), 2014 (8), 2018 (8), 2017 (7), 2025 (7), 2015 (6), 2019 (5), 2009 (3), 2005 (2), K08CA237619 (1), K23HL152013 (1), P20GM130414 (1), P60AR047782 (1), R01AR069000 (1)